Connect with us

Featured

New Regulations Command Drug Companies To Mention List Price On TV Ads

Joe Samuel

Published

on

stock_price_healthcare

Drug companies will have to give list prices for their products in television ads under a new proposal the Trump administration released. In an attempt to restrain the medication costs, the government has issued a proposal, which states that the drug companies need to mention the list prices on TV commercials for those drugs that cost more than $35 for a month’s supply.

Finalized Regulations

The news was unveiled by Health and Human Services Secretary Alex Azar who said the Trump administration has finalized regulations, “What I say to the companies is if you think the cost of your drug will scare people from buying your drugs, then lower your prices. Transparency for American patients is here.”

The new regulation is open for discussion and would affect any drug covered by Medicare or Medicaid. Azar announced the new proposal just hours after the lobby group that represents big drug companies said its members would start indirectly mentioning prices in their television ads.

He further went on saying, “Patients deserve to know what a given drug could cost when they’re being told about the benefits and risks it may have. They deserve to know if the drug company has pushed their prices to abusive levels. And they deserve to know this every time they see a drug advertised to them on TV.”

With the mounting pressure on the drug companies, Azar assured that the administrative body is ready to allow Americans to import lower-priced prescription drugs from abroad. However, the safety measures and the savings that it would bring to the patients are the key factors that would remain intact.

The new regulation is part of the multilevel “blueprint” of President Donald Trump, who has long promised to curtail the drug prices. The details of the pricing probably would appear in a text format and that to towards the end bit of the commercial, when potential side effects are being disclosed. The change in TV commercials should be noticed early by summers.

Democrats Call The Regulation Futile

However, the Democrats hold an opinion that new regulation, which is part of President Donald Trump’s blueprint to rein in high drug costs, is almost futile and would bring not much good to the people. They insisted on Medicare to negotiate the government on behalf of the consumers.

The new regulation also sparked an immediate push back from pharmaceutical companies. Beyond the industry, experts are skeptical about the vagueness of the regulation and it would do anything to bring down prices and may confuse patients because consumers often don’t pay the list price for medications.

Report: Multi-Trillion Dollar Industry Providing Massive Opportunity in 2019 & Beyond

Regulations affecting Medicare and legislative proposals pending in Congress are among the other agenda of Trump’s administration. Realizing the fact that the cost of medicines is the top concern for the voters, Trump along with the lawmakers of both the major political parties want fulfillment that they could vouch for before the 2020 elections.

Drug companies have made vehement objections. The drug companies readily agreed to disclose the prices on their websites and not on the commercials. Johnson & Johnson (JNJ) affirmed the new regulation by announcing that it would start disclosing the cost of its blood thinner, Xarelto, in TV advertising. That drug has a use for treating and preventing blood clots that can cause strokes.

Key Takeaways

Recent government figures highlight that the 10 most commonly advertised drugs have prices ranging from $488 to $16,938 per month. Azar said, “Over $4 billion of pharma spend is in TV ads … that is their most impactful form of advertising. That is where the patient has the most need of being informed.”

However, the regulation would not be relevant to print and radio media. There’s a hope that patients having thorough price information would benefit. They could discuss its affordability with their doctors. But the government feels that they could compel the drug makers to keep a price check. The Trump government hopes that enforcement of the disclosure rule will rely on drug companies suing each other. The suites will likely target violations under a longstanding federal law that governs unfair trade practices.

Most people in America don’t pay the full price for prescriptions. This is the chief reason drugmakers have opposed disclosing the list prices, stating that it would just confuse the public. But insurance plans base their copayments on the list price set by drugmakers. Patients with high-deductible plans or no insurance often pay full price. Their insurance doesn’t start covering until patients have spent several thousand dollars of their own money.

60 days after being published in the Federal Register, the regulation would become a law and be effective.

Continue Reading
Click to comment

Featured

Stock Price Thursday Morning Update – May 16, 2019

Joe Samuel

Published

on

stock price newsletter

Did UPS Drop The Ball? The Biggest Missed Marijuana Industry Opportunity

Marijuana consumption has always been around. But it has always faced public image problems along with its legality. However, as US restrictions on marijuana use become looser, the opportunity for expansion in the industry becomes greater. The combination of convenience and increasing use of marijuana, globally, opens the doors for things like cannabis delivery services. Yet, only a handful of companies are really sinking their teeth into this niche of the marijuana industry and big shippers like UPS & FedEx are dropping the ball. That could mean big opportunities for first movers.

Click Here & Read The Full Article


U.S. Solar Industry Reaches Milestone With 2 Million Installations

The solar installations in the United States have reached a milestone with 2 million solar installations. In fact, the number of solar installations in the United States has officially surpassed 2 million, according to the latest data from Wood Mackenzie Power & Renewables and the Solar Energy Industries Association (SEIA). It is a breakthrough in the solar industry, as it took almost 40 years to install 1 million panels whereas it took only three years since then to reach 2 million.

Is Solar Ready To Boom? Click Here


A New Security Technology Has Begun Turning Heads!

With the world up in arms for more control, companies are scrambling to find a solution. This one, newly publi company could have a solution to address a REAL problem for millions of people across the world

Click Here For Full Report

Continue Reading

Featured

U.S. Solar Industry Reaches Milestone With 2 Million Installations

Joe Samuel

Published

on

solar energy stocks

The solar installations in the United States have reached a milestone with 2 million solar installations. In fact, the number of solar installations in the United States has officially surpassed 2 million, according to the latest data from Wood Mackenzie Power & Renewables and the Solar Energy Industries Association (SEIA). It is a breakthrough in the solar industry, as it took almost 40 years to install 1 million panels whereas it took only three years since then to reach 2 million. It is estimated that in the next two years the figure would cross 3 million.

However, according to Wood Mackenzie it should have actually taken two years to reach the 2 million installation figure. The prediction is indeed weird as the installation of the same has been underestimated by most of the market analysts. Thus, growth is noteworthy.  There is a vivid explanation of the reason behind the prediction of Wood Mackenzie. The figures that we are talking about stand for the number of individual arrays – arrays on the roofs of homes which though comprise a minority of installed capacity, do make up the large majority of individual projects.

Challenges For Solar Power

For all its momentum, the U.S. solar market has not been without its challenges. Despite the decade of incessant growth feat, the U.S solar market collapsed in the first quarter of 2017. This was as a result of the decline in the residential solar market stemming from the decline of the SolarCity/Tesla. However, the market gained the drive and returned to the level it reached in late 2016.

There are several factors that constrained the growth according to Wood Mackenzie and SEIA. Tesla has acquired SolarCity and had dumped its door-to-door sales. Instead, it initiated sales through stores and online through websites. This resulted in the collapse in solar installation and Tesla’s market share.

Residential installations dropped 15 percent between 2016 and 2017, with Tesla’s share showing the most extreme decline during that period, dropping from 650 megawatts to 352 megawatts.  There also had been a substandard possession by SunEdison which compelled Vivint Solar to pull back its sales efforts resulting in a collapse in installations. Thus, the only company emerging triumphant was Sunrun thereby making it one of the three biggest U.S. residential solar companies not to pull back from the market.

Trying extremely hard to grow with lower prices, Tesla has managed to gain customers online, thereby setting pressure of its counterparts. Success in gaining more customers, that too at lower costs, shall determine the time frame the industry would require to install its next million systems — and at what price. Largely due to the challenges of customer acquisition cost, Wood Mackenzie predicts residential growth at just 3.3 percent in 2019.

Despite This, Solar Is Starting To Shine

According to the forecast by Wood Mackenzie, the United States will reach 3 million solar installations in 2021, and 4 million in 2023.  “The rapid growth in the solar industry has completely reshaped the energy conversation in this country,” said Abigail Ross Hopper, president and CEO of trade group SEIA. “This $17 billion industry is on track to double again in five years, and we believe that the 2020s will be the decade that solar becomes the dominant new form of energy generation.”

Looking at a bigger picture, the decline in the costs for lithium-ion batteries and a switch to time-of-use rates, the residential solar companies have started making provisions storage systems along with solar systems. This makes storage a prerequisite as one penetrates deep in key markets.

Continue Reading

Featured

Did UPS Drop The Ball? The Biggest Missed Marijuana Industry Opportunity

Joe Samuel

Published

on

Marijuana consumption has always been around. But it has always faced public image problems along with its legality. However, as US restrictions on marijuana use become looser, the opportunity for expansion in the industry becomes greater. The combination of convenience and increasing use of marijuana, globally, opens the doors for things like cannabis delivery services. Yet, only a handful of companies are really sinking their teeth into this niche of the marijuana industry.

The biggest hurdle for a cannabis delivery service stands on the federal legalization of marijuana. While individual states are legalizing the medicinal and recreational use of marijuana, it is still considered illegal federally. This is significant because it makes interstate trade extremely difficult to the point where it isn’t worth the risk.

Limited Options For Cannabis Delivery

You cannot get marijuana shipped using USPS as they are a federal agency, nor can you utilize UPS, FedEx, or other private shipping companies. This is due to the Department of Justice looking into previous drug malfeasance in 2014. Additionally, the employees for private services can technically go through packages and either take your illegally transported marijuana or report you for financial incentives.

Marijuana industry giants like Canopy Growth (CGC) and Aurora (ACB), haven’t really focused on developing a delivery service. This is because as legality spreads across the continent, so does the delivery range of marijuana mailings. It may take resources and time to develop a delivery service, but the reward could be unimaginable. Take a look at the restaurant industry. When online delivery blew up, it experienced a growth of 300% compared to dining in according to QSR Magazine.

There Are Delivery Options Available – A Good Opportunity For Investors?

Given the industry, investors should consider that this is a very early stage in this particular niche of delivery. Being that very few public companies are entering the space, it may be hard to find a diverse pool of options. But for early marijuana stock investors, they already know all too well that first-mover advantage could be key to grabbing onto an early trend.

Driven Deliveries (DRVD) is a delivery service company for legal marijuana products. While limited in the areas it can reach, the company has grown its business out across California and has been spreading into Nevada and other states. Controlling the California market is huge given the state has the largest marijuana market in the US. It helps the company prepare for less dense markets once they are able to handle California’s market size. The growth for potential is massive as more states begin to flip to pro-marijuana delivery.

To this end, Driven Deliveries just went into expansion mode. It has successfully launched operations in Nevada with Shango Marijuana Dispensary, one of the most successful stores in the State.  The new endeavor provides Driven with a monumental opportunity to serve Las Vegas, the largest market in the State with massive tourism, and a central launch point for additional markets throughout Nevada.

The Nevada cannabis market has been growing at a rapid pace.  Nevada retailers sold approximately $530 million worth of medical and recreational cannabis in 2018.  The $44.1 million in monthly revenue represents a 35% increase when compared to monthly revenue in 2017. According to New Frontier and Arcview Market Research, annual legal cannabis sales in the state are projected to grow to an estimated $629.5 million by 2020.

Investors are Starving for this Tech

Investors’ appetite for such delivery service companies seems to be insatiable. Take DoorDash for example. The company competes with GrubHub and Uber Eats but recently tripled its valuation in only about 5 months to $4 billion despite not even being profitable.

Moreover, Uber Eats owns about 20% of the market while GrubHub, including Seamless and Eat24, has 52% market share. And even in the face of that steep competition, DoorDash has raised nearly $1 billion overall to date. This should give you an idea of just how hungry investors are for on-demand service companies.

Even Chinese investor and WeChat owner, Tencent, is looking to get involved in the food-technology sector in a big way by contributing a significant piece of a $500-$700 million raise for India’s Swiggy. The investment would value Swiggy at $2.5-$3 billion. Another app called Rappi is a Colombian on-demand delivery startup that recently brought in a new round of funding at a valuation north of $1 billion. How will you play the cannabis delivery stock evolution?

marijuana delivery stocks

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


We keep all user information pricate & promise to never spam.*

Privacy Policy

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com